HIV Drug-Resistant Strain Reported

8 June 1997

- Australian researchers have reported the transmission of an HIV strainwhich was resistant to both Glaxo Wellcome's nucleoside reverse transcriptase inhibitor zidovudine and Boehringer Ingelheim's non-nucleoside RTI nevirapine, according to The Journal of Infectious Diseases (June issue). This is believed to be the first documented case of transmission of HIV-1 resistant to two antiretroviral agents, and emphasizes the need to investigate different combinations of drugs which act at different sites of the HIV life cycle, say the authors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight